Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting.
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following the presentation, attendees will have the opportunity to ask q
MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an